Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Perou

Showing results (241-250 of 447) with videos related to

Pageof 45
Sort By:
Biorxiv : the Preprint Server for Biology|February 12, 2026
MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancerAlex J Smith, Zachary Schrank, Nan Guan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2024
The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast CancerYoo Jane Han, Siyao Liu, Ashley Hardeman, et al.
Oncogene|September 14, 2004
Mutation of GATA3 in human breast tumorsJerry Usary, Victor Llaca, Gamze Karaca, et al.
Journal of the National Cancer Institute|October 30, 2016
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 TrialEdith A Perez, Karla V Ballman, Afshin Mashadi-Hossein, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 1, 2025
Identifying locally recurrent versus second primary breast cancer: Genomic versus clinical criteria from Carolina Breast Cancer Study Phase IIISarah C Van Alsten, Michael I Love, Benjamin C Calhoun, et al.
Breast Cancer Research : BCR|March 8, 2019
Separation of breast cancer and organ microenvironment transcriptomes in metastasesMohammad A Alzubi, Tia H Turner, Amy L Olex, et al.
The American Journal of Pathology|March 26, 2011
Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridizationAtocha Romero, Miguel Martín, Maggie C U Cheang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 17, 2007
Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor statusMontserrat Garcia-Closas, Melissa A Troester, Ying Qi, et al.
Clinical Breast Cancer|November 21, 2017
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast CancerAutumn J McRee, Paul K Marcom, Dominic T Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Breast cancer molecular subtypes respond differently to preoperative chemotherapyRoman Rouzier, Charles M Perou, W Fraser Symmans, et al.
Pageof 45

Showing results (241-250 of 447) with videos related to

Sort By:
Pageof 45
Biorxiv : the Preprint Server for Biology|February 12, 2026
MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancerAlex J Smith, Zachary Schrank, Nan Guan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2024
The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast CancerYoo Jane Han, Siyao Liu, Ashley Hardeman, et al.
Oncogene|September 14, 2004
Mutation of GATA3 in human breast tumorsJerry Usary, Victor Llaca, Gamze Karaca, et al.
Journal of the National Cancer Institute|October 30, 2016
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 TrialEdith A Perez, Karla V Ballman, Afshin Mashadi-Hossein, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 1, 2025
Identifying locally recurrent versus second primary breast cancer: Genomic versus clinical criteria from Carolina Breast Cancer Study Phase IIISarah C Van Alsten, Michael I Love, Benjamin C Calhoun, et al.
Breast Cancer Research : BCR|March 8, 2019
Separation of breast cancer and organ microenvironment transcriptomes in metastasesMohammad A Alzubi, Tia H Turner, Amy L Olex, et al.
The American Journal of Pathology|March 26, 2011
Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridizationAtocha Romero, Miguel Martín, Maggie C U Cheang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 17, 2007
Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor statusMontserrat Garcia-Closas, Melissa A Troester, Ying Qi, et al.
Clinical Breast Cancer|November 21, 2017
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast CancerAutumn J McRee, Paul K Marcom, Dominic T Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Breast cancer molecular subtypes respond differently to preoperative chemotherapyRoman Rouzier, Charles M Perou, W Fraser Symmans, et al.
Pageof 45